The recruitment status of this trial is unknown because the information has not been verified recently.

Condition type 2 diabetes
Sponsor University of Kentucky
Collaborator American Diabetes Association
Start date October 2013
End date September 2016
Trial size 0 participants
Trial identifier NCT01917669, 13-0571-F1V


The purpose of this research is to better understand how calcium and glucose may play a role in people developing diabetes. By doing this study, the investigator hopes to learn whether abnormal calcium and glucose responses in skin biopsies from healthy patients and patients with Type 2 diabetes can identify and predict patients at greatest risk for later complications.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
These patients are anticipated to have elevated BMI, yet not be diabetics.
These patients will have good glucose control.
These patients are anticipated to have poor glucose control. They are usually taking insulin.

Primary Outcomes

Are peak (nM) calcium responses to bradykinin enhanced along the continuum of disease in skin fibroblasts from the 4 patient groups?
time frame: Three years

Secondary Outcomes

Are glucose utilization rates (a.u./min) measured in skin fibroblasts from the 4 patient groups different with disease progression?
time frame: Three years

Eligibility Criteria

Male or female participants from 40 years up to 55 years old.

Inclusion Criteria: - Healthy - Type 2 Diabetes Exclusion Criteria: - Under 40 years of age - Over 55 years of age - Pregnant or breastfeedig - Will not agree to a skin biopsy - Talking calcium channel blockers

Additional Information

Official title A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health
Description The overall goal of this proposal is to establish a pathophysiological index of a patient's status through imaging of calcium and glucose in skin fibroblasts. The investigator will obtain skin samples from patients in the Barnstable Brown Obesity and Diabetes Center at the University of Kentucky to test the hypothesis that calcium and glucose dysregulation are present in fibroblasts from patients with Type 2 diabetes, and are exaggerated in more difficult-to-treat patients or those with poor glucose control. The innovation of the project focuses on results that can potentially lead to earlier treatment for patients with diabetes and thereby reduce the risk for long-term complications. Three levels of analyses will be conducted to assess the relationship between Ca2+ and glucose homeostasis in four patient groups (lean non-diabetics, obese non-diabetics, Type 2 Diabetics with good glucose control, and Type 2 Diabetics with poor control. Participants will be required to attend only one study visit that will last approximately 2-3 hours. During the study subject will undergo the following: 1. Collection of two 4 ml tubes of blood for adiponectin analysis, 2. A skin biopsy, 3. Collection and review of medical history and current/past medication use 4. Collection of demographic information, 5. Height and weight measurement 6. Body mass index evaluation, 7. Vital signs assessment (blood pressure, pulse). Follow-up for all enrolled patients will occur on a yearly basis through a phone interview. The punch biopsy will be performed under local anesthesia.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University of Kentucky.